Abstract： Branch retinal vein occlusion(BRVO)is a prevalent ocular pathology in clinical practice,which may potentially cause irreversible damage upon patients'visual acuity and consequently pose a substantial threat to overall human well-being.Macular edema(ME)emerges as a prevalent sequelae of BRVO,and as of now,there lacks a definitive pharmaceutical intervention for its management.Consequently,development of drugs targeting BRVO and secondary ME matters much.This article comprehensively reviewed the recent advance in pharmaceutical research on the treatment of BRVO and secondary ME.